JP7603612B2 - 治療法 - Google Patents

治療法 Download PDF

Info

Publication number
JP7603612B2
JP7603612B2 JP2021563064A JP2021563064A JP7603612B2 JP 7603612 B2 JP7603612 B2 JP 7603612B2 JP 2021563064 A JP2021563064 A JP 2021563064A JP 2021563064 A JP2021563064 A JP 2021563064A JP 7603612 B2 JP7603612 B2 JP 7603612B2
Authority
JP
Japan
Prior art keywords
seq
protein
nomacopan
substituted
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530068A (ja
JP2022530068A5 (https=
Inventor
エイチ ウェストン－デヴィズ，ワイン
コールダー，ヴァージニア
Original Assignee
ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴォリューション イミュノ ファーマシューティカルズ エスエイ filed Critical ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Publication of JP2022530068A publication Critical patent/JP2022530068A/ja
Publication of JP2022530068A5 publication Critical patent/JP2022530068A5/ja
Application granted granted Critical
Publication of JP7603612B2 publication Critical patent/JP7603612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021563064A 2019-04-25 2020-03-04 治療法 Active JP7603612B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1905810.6 2019-04-25
GBGB1905810.6A GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment
GB2000955.1 2020-01-22
GBGB2000955.1A GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment
PCT/EP2020/055741 WO2020216513A1 (en) 2019-04-25 2020-03-04 Method of treatment

Publications (3)

Publication Number Publication Date
JP2022530068A JP2022530068A (ja) 2022-06-27
JP2022530068A5 JP2022530068A5 (https=) 2023-03-13
JP7603612B2 true JP7603612B2 (ja) 2024-12-20

Family

ID=66810336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563064A Active JP7603612B2 (ja) 2019-04-25 2020-03-04 治療法

Country Status (10)

Country Link
US (1) US20220211810A1 (https=)
EP (1) EP3958974A1 (https=)
JP (1) JP7603612B2 (https=)
KR (1) KR20220018963A (https=)
CN (1) CN114072206B (https=)
AU (1) AU2020263709A1 (https=)
CA (1) CA3137240A1 (https=)
GB (2) GB201905810D0 (https=)
IL (1) IL287250A (https=)
WO (1) WO2020216513A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024238859A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521194A (ja) 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
JP2018530574A (ja) 2015-10-07 2018-10-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の加齢黄斑変性を治療する方法
WO2018193120A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
WO2018193121A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin variants lacking c5 binding

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
SI2173890T1 (sl) * 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
SG11201811491YA (en) * 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
AU2018226872A1 (en) * 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
US11730792B2 (en) * 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
US20220370556A1 (en) * 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521194A (ja) 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
JP2018530574A (ja) 2015-10-07 2018-10-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の加齢黄斑変性を治療する方法
WO2018193120A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
WO2018193121A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin variants lacking c5 binding

Also Published As

Publication number Publication date
JP2022530068A (ja) 2022-06-27
GB202000955D0 (en) 2020-03-04
EP3958974A1 (en) 2022-03-02
US20220211810A1 (en) 2022-07-07
CN114072206A (zh) 2022-02-18
CA3137240A1 (en) 2020-10-29
AU2020263709A1 (en) 2021-12-23
GB201905810D0 (en) 2019-06-05
WO2020216513A1 (en) 2020-10-29
IL287250A (en) 2021-12-01
CN114072206B (zh) 2024-11-08
KR20220018963A (ko) 2022-02-15

Similar Documents

Publication Publication Date Title
CN110896606B (zh) 用于治疗自身免疫性水疱病的coversin
US20180133288A1 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
JP7603612B2 (ja) 治療法
US11596667B2 (en) Method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
JP2018535696A (ja) 遺伝子構築物
US9260506B2 (en) Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
CA2666843C (en) Treatment of age-related macular degeneration and other diseases of the eye
JP2020517643A (ja) 瘢痕性眼炎症障害の治療のためのコバーシン
EP3675889A2 (en) Angio-3 for treatment of retinal angiogenic diseases
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
WO2005118799A1 (en) Ovine hyaluronidase
WO2013005603A9 (ja) 結膜におけるアレルギー性炎症の予防及び／又は治療剤
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
AU2012385960A1 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
WO2024115767A1 (en) Nomacopan-pas fusion proteins
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20220121

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20220120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241210

R150 Certificate of patent or registration of utility model

Ref document number: 7603612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150